- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03015922
Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma (MUKeleven)
January 21, 2020 updated by: Gordon Cook, University of Leeds
VIRel: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN® (Pelareorep) in Combination With Lenalidomide or Pomalidomide
This study will recruit patients currently receiving either lenalidomide or pomalidomide whose disease is relapsing.
This is a dose escalation study and the aim is to determine the maximum tolerated dose (MTD) of REOLYSIN® that can be given in combination with lenalidomide or pomalidomide.
The study will also investigate the safety, side effects and effectiveness of this treatment combination.
Pomalidomide and lenalidomide will be evaluated separately as two separate groups.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leeds, United Kingdom
- St James's University Hospital
-
Sheffield, United Kingdom
- Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosed with symptomatic multiple myeloma (according to IMWG 2014 criteria)
- Evaluable disease by modified IMWG criteria (i.e. by abnormal serum M protein, urinary M protein or serum free light chain assays)
- Currently receiving either lenalidomide or pomalidomide therapy, alone or in combination with other myeloma therapy, with evidence of serological or clinical disease progression as defined by IMWG criteria (2011)
- Life expectancy of ≥ 3 months
- ECOG performance status of ≤2
- Required laboratory values within 14 days prior to dose allocation:
- Absolute neutrophil count ≥ 1.0 x10^9 /L. (growth factor support is not permitted)
- Platelet count ≥ 70 x 10^9/L. (platelet support is not permitted; platelets < 70 but ≥ 25 acceptable if bone marrow is > 50% infiltrated by MM)
- Haemoglobin ≥ 8 g/dL. Blood support is permitted
- Serum bilirubin ≤ 2 x upper limit of normal (ULN)
- ALT or AST ≤ 2.5 x ULN
- Serum creatinine ≤ 2 x ULN
- Corrected calcium ≤ 2.8 mmol/l
- Negative HIV and viral (B and C) hepatitis test result within 14 days prior to dose allocation
- Able to give informed consent and willing to follow trial protocol
- Aged 18 years or over
- All participants must agree to follow the Celgene Pregnancy Prevention Programme (PPP) and participate in the counselling associated with this:
- Females of childbearing potential (FCBP) must agree to utilise two reliable forms of contraception simultaneously or practice complete abstinence for at least for 28 days prior to starting trial treatment, during the trial and for at least 28 days after trial treatment discontinuation, and even in case of dose interruption, and must agree to Celgene PPP pregnancy testing during this timeframe
- Females must agree to abstain from breastfeeding during trial participation and 28 days after trial drug discontinuation
- Males must agree to use a latex condom during any sexual contact with FCBP (or must practice complete abstinence) during the trial, including during dose interruptions and for 28 days following discontinuation from this trial even if he has undergone a successful vasectomy
- Males must also agree to refrain from donating semen or sperm while on pomalidomide including during any dose interruptions and for 28 days after discontinuation from this trial
- All participants must agree to refrain from donating blood while on trial drug including during dose interruptions and for 28 days after discontinuation from this trial
Exclusion Criteria:
- Non-secretory multiple myeloma
- Pregnant (positive pregnancy test) in line with the Celgene Pregnancy Prevention Programme or breast feeding
- Previous anti-tumour therapies including experimental agents, other than lenalidomide or pomalidomide, within 28 days of the start of protocol treatment. Steroid therapy is permitted, but must be stopped 48 hours prior to cycle 1 day 1
- Concurrent or previous malignancies (<12 months post end of treatment) at other sites, with the exception of appropriately treated localised epithelial skin or cervical cancer, or incidental histologic findings of prostate cancer (TNM stage T1a or 1b). Participants with histories (≥12 months) of other tumours, in remission and not currently on therapy, may be entered
- System corticosteroid therapy for comorbidities (i.e. medical conditions other than multiple myeloma) that cannot be stopped for the duration of the trial. Topical corticosteroid therapy is not an exclusion criterion.
- Any history of known hypersensitivity to any of the trial medications or excipients
- Active symptomatic fungal, bacterial, and/or viral infection
- Poorly controlled or serious medical or psychiatric illness that, in the Investigator's opinion, is likely to interfere with participation and/or compliance in this clinical trial
- Patients with significant cardiovascular disease (e.g. history of congestive heart failure requiring therapy (≥ NYHA Class III), presence of severe valvular heart disease, presence of an atrial or ventricular arrhythmia requiring treatment, uncontrolled hypertension, or history of QTc abnormalities)
- Radiotherapy or major surgery within 4 weeks prior to registration
- Greater than or equal to grade 2 neuropathy, with or without pain
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lenalidomide or pomalidomide, plus REOLYSIN
Lenalidomide capsules, oral, maximum 10mg daily on days 1-21 of 28-day cycles. OR Pomalidomide capsules, oral, maximum 1mg daily on days 1-21 of 28-day cycles. Plus (all patients): REOLYSIN® , intravenous infusion, maximum 3x10^10 TCID50 on days 1, 8, 15 and 22 of 28-day cycles. |
Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
Patients will receive Reolysin alongside either lenalidomide or pomalidomide
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicities
Time Frame: After cycle 1 (28 days) of treatment. Assessed in real-time for each patient to inform dose escalation decisions.
|
Dose-limiting toxicities (DLTs), within the first cycle (until cycle 2, day 1), in order to establish the Maximum Tolerated Dose (MTD) of REOLYSIN® in combination with lenalidomide or pomalidomide, in two separate groups of participants.
|
After cycle 1 (28 days) of treatment. Assessed in real-time for each patient to inform dose escalation decisions.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety profile of REOLYSIN® and lenalidomide
Time Frame: Until 28 days after the last dose of trial treatment for each patient. Assessed up to 27 months.
|
Safety will be reported based on the occurrence of SAEs, SARs and SUSARs.
|
Until 28 days after the last dose of trial treatment for each patient. Assessed up to 27 months.
|
Safety profile of REOLYSIN® and pomalidomide
Time Frame: Until 28 days after the last dose of trial treatment for each patient. Assessed up to 27 months.
|
Safety will be reported based on the occurrence of SAEs, SARs and SUSARs.
|
Until 28 days after the last dose of trial treatment for each patient. Assessed up to 27 months.
|
Toxicity profile of REOLYSIN® and lenalidomide
Time Frame: Until 28 days after the last dose of trial treatment fior each patient. Assessed up to 27 months.
|
Toxicity will be reported based on adverse events, as graded by CTCAE V4.0, and determined by routine clinical assessments at each centre.
|
Until 28 days after the last dose of trial treatment fior each patient. Assessed up to 27 months.
|
Toxicity profile of REOLYSIN® and pomalidomide
Time Frame: Until 28 days after the last dose of trial treatment fior each patient. Assessed up to 27 months.
|
Toxicity will be reported based on adverse events, as graded by CTCAE V4.0, and determined by routine clinical assessments at each centre.
|
Until 28 days after the last dose of trial treatment fior each patient. Assessed up to 27 months.
|
Response rate (stable disease or better) after 6 cycles of therapy
Time Frame: Data will be collected from each patient after they have received 6 cycles of therapy, if this stage is reached. 6 cycles are expected to take 24 weeks to complete.
|
Measured only in patients treated at the maximum tolerated dose
|
Data will be collected from each patient after they have received 6 cycles of therapy, if this stage is reached. 6 cycles are expected to take 24 weeks to complete.
|
Maximum response within 6 cycles of therapy
Time Frame: Assessed for each patient after they have received 6 cycles of treatment. 6 cycles are expected to take 24 weeks to complete.
|
Measured only in patients treated at the maximum tolerated dose
|
Assessed for each patient after they have received 6 cycles of treatment. 6 cycles are expected to take 24 weeks to complete.
|
Maximum response overall
Time Frame: Assessed for each patient after they have completed treatment on the trial. Assessed up to 27 months.
|
Measured only in patients treated at the maximum tolerated dose
|
Assessed for each patient after they have completed treatment on the trial. Assessed up to 27 months.
|
Time to maximum response
Time Frame: Assessed for each patient after they have completed treatment on the trial. Assessed up to 27 months.
|
Measured only in patients treated at the maximum tolerated dose
|
Assessed for each patient after they have completed treatment on the trial. Assessed up to 27 months.
|
Progression-free survival
Time Frame: Calculated for each patient from the date of registration up to first documented evidence of disease progression or death. Assessed up to 27 months.
|
Measured only in patients treated at the maximum tolerated dose.
Participants who have not progressed at the time of analysis will be censored at the last date they were known to be alive and progression free.
|
Calculated for each patient from the date of registration up to first documented evidence of disease progression or death. Assessed up to 27 months.
|
Overall survival
Time Frame: Calculated for each patient from the date of registration to death. Assessed up to 27 months.
|
Measured only in patients treated at the maximum tolerated dose.
Participants who have not died at the time of analysis will be censored at the last date they were known to be alive.
|
Calculated for each patient from the date of registration to death. Assessed up to 27 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune response biomarker profile of REOLYSIN and lenalidomide administered in combination
Time Frame: This will be assessed based on samples taken throughout each patient's time on the trial. Assessed up to 27 months.
|
Biomarker profiling of the combination treatment
|
This will be assessed based on samples taken throughout each patient's time on the trial. Assessed up to 27 months.
|
Immune response biomarker profile of REOLYSIN® and pomalidomide administered in combination
Time Frame: This will be assessed based on samples taken throughout each patient's time on the trial. Assessed up to 27 months.
|
Biomarker profiling of the combination treatment
|
This will be assessed based on samples taken throughout each patient's time on the trial. Assessed up to 27 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gordon Cook, St. James's University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 5, 2017
Primary Completion (Anticipated)
September 1, 2021
Study Completion (Anticipated)
October 1, 2021
Study Registration Dates
First Submitted
November 16, 2016
First Submitted That Met QC Criteria
January 6, 2017
First Posted (Estimate)
January 10, 2017
Study Record Updates
Last Update Posted (Actual)
January 22, 2020
Last Update Submitted That Met QC Criteria
January 21, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Pomalidomide
- Lenalidomide
Other Study ID Numbers
- HM16/118
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Lenalidomide or Pomalidomide
-
Onward TherapeuticsRecruitingSolid Tumor | Hematological MalignancyFrance
-
PfizerCompletedMultiple MyelomaCanada, United States
-
University Health Network, TorontoCompletedMultiple Myeloma | AmyloidosisCanada
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
Janssen Research & Development, LLCRecruitingMultiple MyelomaUnited States, Belgium, United Kingdom, Netherlands, France, Australia
-
TakedaActive, not recruitingMultiple MyelomaUnited States, Switzerland, Belgium, Spain, Israel, Italy, Austria, Canada, United Kingdom
-
Bristol-Myers SquibbRecruitingRelapsed or Refractory Multiple MyelomaTaiwan
-
Ascentage Pharma Group Inc.RecruitingMultiple Myeloma | AmyloidosisUnited States
-
Kirby InstituteActive, not recruitingHigh Grade Squamous Intra-epithelial Lesion (HSIL)Australia
-
Amsterdam UMC, location VUmcNot yet recruitingMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory